HERTHENA-Breast04 Trial Starts for HR+ HER2- Breast Cancer Patients
August 27, 2025
The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evaluating the efficacy and safety of investigational patritumab deruxtecan (HER3-DXd) versus investigator’s choice of treatment